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Abstract
Background: Postmenopausal women are prone to develop functional disabilities as a result of reduction in
muscle strength and muscle mass caused by diminished levels of female sex hormones. While hormone
replacement therapy may counteract these changes, conventional hormone replacement therapy is associated
with potential harmful effects, such as an increased risk of breast cancer, and its prescription is not recommended.
For this reason newer alternative drugs, such as tibolone, a synthetic steroid with estrogenic, progestogenic and
androgenic activity, and raloxifene, a selective estrogen receptor modulator, may be more appropriate. This trial
investigates the effect of tibolone and raloxifene on muscle strength.
Methods: We recruited 318 elderly women in our single-center randomized, double-blind, double-dummy,
placebo-controlled trial. Participants were randomized to tibolone 1.25 mg (Org OD 14, Organon NV, the
Netherlands) plus placebo, raloxifene 60 mg (Evista®, Eli Lilly, United States) plus placebo or two placebo tablets
daily for 24 months.
The primary aim is to determine if there is a difference between tibolone and placebo or if there is a difference
between raloxifene and placebo. Primary endpoints are muscle strength and bone mineral density. The secondary
endpoints are postural balance, body composition, cognitive function, anxiety, mood and quality of life. The
secondary aim is to determine if there is a difference between tibolone and raloxifene.
The measure of effect is the change from the baseline visit to the visits after 3 months, 6 months, 12 months, and
24 months. A follow-up measurement is planned at 30 months to determine whether any effects are sustained
after cessation of the study. By December 2007 the blind will be broken and the data analyzed.
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Background
Aging is associated with muscle atrophy, physical frailty,
and impaired cognitive function. This functional decline
can severely affect quality of life and reduce the likelihood
of a person being able to live independently. Women are
more vulnerable to the effects of this age-related muscle
loss because their peak muscle mass is lower than that of
men and around the time of menopause they experience
an additional 15% loss of muscle mass [1-3]. Hormonal
replacement therapy (HRT) in postmenopausal women
may prevent muscle strength decline [2,4-9]. Unfortu-
nately, however conventional hormone replacement ther-
apy has serious side-effects such as an increased risk of
breast cancer, thrombo-embolism, cholecystitis, stroke
and coronary events, especially in elderly women. Unop-
posed estrogen replacement therapy increases the risk of
endometrial carcinoma. [10,11]
For this reason, newer drugs, such as tibolone, a synthetic
steroid with oestrogenic, progestogenic, and androgenic
activity, and raloxifene, a selective estrogen receptor mod-
ulator, may be more attractive.
Tibolone is a tissue-specific compound that has favorable
effects on bone, vagina, climacteric symptoms, mood, and
sexual well-being in postmenopausal women, without
having an estrogen-like stimulating effect on the
endometrium or breast [12]. In a randomized, placebo-
controlled and double-blind trial involving early post-
menopausal women, handgrip strength increased by
about 4% after 1 year of treatment with tibolone 2.5 mg
[13]. Tibolone 1.25 mg may be effective in preventing
osteoporosis and post-menopausal symptoms.
Selective estrogen receptor modulators (SERMs) are a
diverse group of compounds that bind with specificity
and high affinity to estrogen receptors (ER) consisting of
the ER α and the ER β. SERMs can act as either ER agonists
or antagonists, depending on the tissue type. Raloxifene
hydrochloride is a nonsteroidal benzothiophene with
estrogen agonistic effects on bone, serum lipids, and the
arterial vasculature and with estrogen antagonistic effects
in the breast and uterus [14]. Raloxifene has been
approved for osteoporosis prevention and the treatment
of postmenopausal osteoporosis in several countries. Its
actions on bone are similar to those of estrogens [15].
Relatively little is known about the effects of estrogen sup-
plementation, with regard to frailty, initiated later in the
postmenopausal period (> 70 years) and even less is
known about the effects of tibolone and raloxifene on
muscle strength, body composition, bone mineral density
(BMD), balance, cognitive function and mood/depres-
sion in late postmenopausal women. The purpose of this
study is to determine whether these newer drugs have
beneficial effects in older postmenopausal women.
Design and Methods
The study is a single-center, randomized, double-blind,
double-dummy, placebo-controlled trial to evaluate the
effect of tibolone and raloxifene on skeletal muscle
strength, body composition, BMD, balance, cognitive
function, mood/depression, anxiety and quality of life in
late postmenopausal women aged ≥ 70 years. The aim was
to recruit 325 study subjects, so that, after allowing for a
drop out rate of 30 % over 2 years, data could be collected
from 225 women.
Participants were randomly assigned by the hospital phar-
macy of the University Medical Center of Utrecht using
computerprogramm "Design" to one of the three treat-
ment groups in a 1:1:1 ratio after baseline measurements
had been taken. The sub-blocks contained 12 numbers.
The design is double-blind. We do not expect that
unblinding by symptoms will occur. In a diary we actively
inquired about leg cramps and flushing. These have been
reported to be side effects of raloxifene, but only in 0–
10% for legcramps and more than 10% for flushing [16].
Legcramps also occur often in women of this age.
The treatment period was 24 months, with 1 month being
considered to be 28 days. Assessments were performed at
baseline and after 3, 6, 12, and 24 months. Participants
will also be assessed at 30 months, to determine whether
treatment has a lasting effect. The Institutional Review
Board of the University of Medical Center Utrecht
approved the study protocol. All participants gave written
informed consent at the screening visit.
Inclusion criteria
-Healthy postmenopausal women;
-Minimum age 70 years at the time of inclusion;
-Body mass index between 18 and 35 kg/m2,
-Subjects should be willing and able to comply with the
protocol for the duration of the study, after written
informed consent.
Exclusion criteria
-Steroid therapy or other drugs affecting muscle mass
taken during the last 6 months;
-History or presence of any malignancy (except non-
melanoma skin cancers);
-Undiagnosed abnormal vaginal bleeding in the past year
prior to screening;Trials 2008, 9:32 http://www.trialsjournal.com/content/9/1/32
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-Presence or history of endometrial hyperplasia with or
without atypia;
-Presence or history of cardiovascular, cerebrovascular or
thrombo-embolic disorders;
-Current liver or renal disease or history of this condition;
-Uncontrolled hypertension (systolic blood pressure ≥
170 mm Hg systolic and/or diastolic blood pressure ≥ 105
mm Hg);
-Osteoporosis: Z-score < -2
-Bone disease other than osteoporosis such as Paget's dis-
ease;
-Osteomalacia or bone metastases;
-Alcohol abuse (average intake of more than 4 alcohol
containing units per day);
-Smoking more than 10 cigarettes/day;
-Use of sex hormones, corticosteroids, insulin, anti-coag-
ulants or enzyme-inducing drugs;
-Treatment with tibolone or raloxifene within the last 6
months;
-Known hypersensitivity to tibolone or raloxifene;
-Presence of any condition, concomitant disease, intercur-
rent illness or resultant therapy that would interfere either
with the participants' compliance or with the results of the
study and/or their evaluation;
-Major problems with locomotion and cognitive impair-
ment (MMSE < 24);
-Participation in another study.
Recruitment
Recruitment started on 23 July 2003 by means of an
advertisement placed in the local newspaper (reaching
194.000 households, only a few involving women 70
years or older). Interest in the study was expressed by 80
women; 38 women were randomized. Further recruit-
ment was done by mailing 16.090 women aged 70–80
years whose addresses were selected by the municipal reg-
ister of the cities Utrecht, Zeist, Houten, Bilthoven, and
Driebergen. Women who previously participated in
research at the geriatric department were also recruited
(table 1).
Women were asked to complete a questionnaire about the
type of medication used, number of falls, troubles walk-
ing, use of a walking aid, dyspnea, history of thrombosis,
liver complaints, hysterectomy or uterine complaints,
weight, and height. Women who did not meet the inclu-
sion criteria were sent a letter thanking them for their
interest. Those who met the inclusion criteria and who
were still interested in participation were invited, by tele-
phone, to a screening visit. During this telephone conver-
sation, the participant's medical history was checked for
exclusion criteria.
Two hundred and seven women were excluded and 87
women refused to participate or there were other reasons
for exclusion. Reasons for exclusion after a positive reac-
tion and after screening are given in table 2 and 3. A flow
chart of study recruitment is given in figure 1.
Information and screening
At the screening visit women were informed about the
trial and gave their written informed consent. A medical
and gynecological history was obtained and medication
use was recorded. Blood pressure, heart rate, weight, and
height were measured and mamma palpation, cardial,
pulmonal and abdominal examinations were performed.
In- and exclusion criteria were checked again using a list
of questions. Finally, a Mini Mental State Examination
was performed. Forty women were excluded after screen-
ing (table 3). Within 28 days of the screening visit, base-
line measurements were taken and the participants were
randomized.
Randomization visit and baseline assessments
Baseline measurements were taken within 28 days of
screening at the time of randomization. Mammography
Table 1: Recruitment, inclusion and exclusion.
Recruitment Total Positive response Exclusion after 
positive reaction
Exclusion after 
screening
Inclusion Never started
Local newspaper: unknown 80 38 4 38 6
UMC group 172 32 8 8 16 3
Local municipal registers 16090 541 249 28 264 26
total 16262 653 295 40 318 35Trials 2008, 9:32 http://www.trialsjournal.com/content/9/1/32
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was performed in all women except those who had had a
mammography within 12 months before randomization.
If there was an abnormality, malignancy or dubious
malignancy, the participant was excluded. Dual Energy X-
ray Absorptiometry (DEXA) was performed to measure
BMD. If the z-score was lower than -2, the subject was
excluded; if the z-score was between -1 and -2, the subject
was given calcium supplements and entered the trial.
At baseline muscle strength and power were measured
and functional mobility was assessed with the timed "up
and go test". Postural balance was determined with body
sway and functional reach. Women completed the
Women's Health Questionnaire (WHQ) to determine
quality of life. Other questionnaires administered were on
habitual physical activity (HPA), the State Trait Anxiety
Inventory (STAI) and the Geriatric Depression Scale. Cog-
nitive function was determined with a 15 word test and a
trail B test. The tests used at successive visits are given in
table 4.
Randomization started at July 15th 2003. Three hundred
and eighteen women were randomized. Thirty-five
women were excluded after randomization because of
osteoporosis (n = 13), mamma carcinoma or abnormality
on mammography (n = 6), hypertension (n = 1), polymy-
algia rheumatica (n = 1) and some women decided to
withdraw from the study at this stage (n = 14). Partici-
pants were randomized to receive tibolone 1.25 mg (Org
OD 14, Organon NV, the Netherlands) plus placebo,
raloxifene 60 mg (Evista®, Eli Lilly, United States) plus pla-
cebo or two placebo tablets daily for 24 months. Because
the results of the Long term Intervention on Fractures with
Tibolone (LIFT)-study suggested there was a higher risk of
cerebrovascular accidents with tibolone use after an aver-
age of 2.4 years (hazard ratio 2.3), our research group
decided to stop the tibolone arm of the study on February
2006 [17]. One hundred and five women were rand-
omized to use tibolone. Of those women 15 never started
the study, 27 already dropped out 15 after baseline, 5 after
3 months, 3 after six months, 4 after one year measure-
ments), and 19 women had to stop the study before one
year measurements were reached. Available one-year data
about the tibolone group (n = 44) will be analysed.
Measurements
The following primary parameters were used to determine
the effect of the study medication
Muscle strength and muscle power
Maximum voluntary isometric knee extension strength
(both legs) was measured as the force applied at the ankle,
with the subject seated in an adjustable straight-back
chair, the lower leg unsupported and the knee flexed to
90°. Force was measured with a strain gauge and recorded
with a strain meter [18,19].
Explosive leg extensor power (both legs) was assessed
with the Nottingham Power Rig. The subject, in a seated
position with folded arms, gave a maximal push to a large
foot pedal setting a flywheel in motion. The initial fly-
wheel speed reflects the leg extensor power of the subject
[20]. The measurement was repeated for at least five
efforts, until no further improvements were seen.
Handgrip strength (both hands), which is associated with
general muscle strength, was measured with a handgrip
Table 2: Reasons for exclusion after positive response
Exclusion reason: Total:
Subject does not want to 79
Already involved in another study 2
BMI > 33 or < 18 28
Cardiovascular disease 42
Hypertension 3
Thrombo-embolic disease 33
Malignancy 26
COPD 1
Liver problem 2
Decreased functionalability 3
On hormone replacement therapy 22
Contra-indicated medication 46
Parkinsonism 1
Osteoporosis 1
Two-sided hip prothesis 5
Moved to Spain/Belgium 2
General practitioner advised not to participate 1
Total 294
Table 3: Exclusion after screening.
Exclusion reason: Number:
Malignancy 3
Benign abnormality 4
Medication 4
Hypertension 4
BMI > 35 2
Angina pectoris 4
TIA 1
Thrombosis 2
Untreated diabetes mellitus 1
Surgery 1
Own reasons 9
MMSE < 24 3
Skin problems 1
Pain/functional disability 1
total 40Trials 2008, 9:32 http://www.trialsjournal.com/content/9/1/32
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mechanical dynamometer [21]. The best of at least three
attempts for each hand was recorded.
Bone mineral density (BMD)
BMD, measured by DEXA, was measured at the lumbar
vertebrae (L1–L4, calculated from the total bone mineral
content and the total area of the four lumbar vertebrae)
and at the hip (neck, trochanter, and intertrochanteric
region). DEXA scanner precision was carefully registered
by means of a dedicated Hologic spine phantom. DEXA
measurements were conducted at the Julius Center for
Health Sciences and Primary Care, University Medical
Center Utrecht, the Netherlands.
The following secondary parameters were used to deter-
mine the effect of the study medication:
Flowchart representing recruitment after a newspaper advertisement and after invitation of women ≥ 70 years selected by  municipal registers of several cities and women who participated before in a study of the geriatric department Figure 1
Flowchart representing recruitment after a newspaper advertisement and after invitation of women ≥ 70 
years selected by municipal registers of several cities and women who participated before in a study of the ger-
iatric department. Suitable women were invited for a screening visit. They were included in the trial if they met the inclusion 
criteria and after written informed consent. Then randomization took place.Trials 2008, 9:32 http://www.trialsjournal.com/content/9/1/32
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Functional mobility, balance, endurance and body composition
Functional mobility was assessed quantitatively with the
timed "get up & go" test [22]. The subject performed the
test three times as fast as possible and the fastest time
(recorded in seconds) was used for analysis.
Postural balance was assessed by means of an analysis of
body sway and by the functional reach test. Body sway
was assessed with both eyes open and both eyes closed
[23]. In the Functional Reach the maximal push is
recorded in cm [24].
Endurance was measured with the 6-minute walking test.
(modified Cooper test) [25]. Body composition was
measured by bio-electrical impedance analysis (BIA) and
by DEXA. DEXA measurements were only performed at
baseline and 24 months. The principle of BIA is that lean
tissues, which mainly consist of electrolyte-containing
water, readily conduct an applied current, whereas fat
does not or only minimally. A current of 800 μA at a signal
frequency of 50 Hz was generated by a bioelectrical
impedance analyzer and was applied to the subject
through electrodes that were placed on the wrist and the
ankle on one side of the body [26]. Total body fat distri-
bution and four sub-regions of leg fat distribution were
determined from the DEXA scans [27,28].
Quality of life, well-being and mood/depression
Quality of life was measured with the Women's Health
Questionnaire (WHQ) and the EQ-5D questionnaire
[29,30]. The EuroQol (EQ-5D) questionnaire was devel-
oped by a European group as a standard non-disease-spe-
cific instrument for describing and valuing quality of life
(EuroQol, Kind). It is a descriptive classification system
consisting of five items, each with three levels. [31-33]
Mood/depression was measured with the Geriatric
Depression Scale (GDS). This test is designed to assess for
depression in older adults, independent of somatic symp-
toms [34,35]. It can also be used as indicator of severity of
psychopathology.
Anxiety was measured with the Dutch Version of the State-
Trait Anxiety Inventory (Self-Judgment Questionnaire =
STAI-DY). The STAI was specifically designed to be self-
administered. The test has a uniformly high level of inter-
nal consistency [36,37].
Cognitive function (15 Words test; Trails B test)
Cognitive function was assessed with the Groningen 15
Words test [38,39] and the Trails B test. The Groningen 15
Words test is an improved version of a test originally
devised by Rey [40]. Briefly, 15 words are presented, one
after another. Then the subject is asked to recall as many
words as she can. This procedure is repeated 5 times, so
that a learning curve can be plotted. The total number of
words and the maximum number of words recalled over
five trials are taken as dependent measures of learning and
short-term memory. After a delay of 20 minutes (during
which another test is administered), a recall trial is carried
out without presentation of the list. The score at this
delayed recall comprises the long-term memory score. The
Trails B test measures speeded mental operations, atten-
tion, visual scanning, visual sequential abilities, and men-
tal flexibility. The test is sensitive to aging effects [41,42].
Table 4: Examinations and assessments.
Assessment Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7
screen Base mnth3 mnth6 mnth12 mnth24 mnth30
Medical history X
Physical examination X
Gynaecologicol examination X
Breast examination X
Mammography* X
In/exclusion criteria X
V i t a l  s i g n s X X X X XXX
Bone mineral density X X
Body composition X X X X X X
Muscle strength X X X X X X
Cognitive function X X X X X X
Functional mobility X X X X X X
Mood/depression X X X X X X
Quality of life X X X X X X
HPA X X X X X X
Adverse events X X X X
Drug accountability X X X X
* Only if not performed in the year before.Trials 2008, 9:32 http://www.trialsjournal.com/content/9/1/32
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Compliance monitoring
Compliance with treatment was checked by means of a
diary card and by counting the remaining tablets at each
visit. Subjects who missed more than 6 days of trial med-
ication in 4 weeks were excluded.
Adverse event/Serious adverse event
The investigator decided whether an abnormal labora-
tory/vital sign was clinically relevant and should be
entered on the adverse event form. If the AE met the defi-
nition of a serious adverse event (SAE), the procedure for
SAEs was followed.
Serious adverse event was defined as any untoward medi-
cal occurrence that at any dose results in death, is life-
threatening, requires in-patient hospitalization or prolon-
gation of existing hospitalization, or results in persistent
or significant disability/incapacity. It should be noted the
term 'life-threatening' refers to an event in which the
patient was at risk of death at the time of the event; it does
not refer to an event that hypothetically might have
caused death if it had been more severe.
Medical and scientific judgment was exercised in deciding
whether major medical events that were not be immedi-
ately 'life-threatening' or result in death or hospitalization
but which might jeopardize the patient or might require
intervention to prevent one of the other outcomes listed
in the definition above should be considered serious. All
SAE's were reported to the Institutional Review Board of
the University Medical Center of Utrecht, Utrecht, the
Netherlands, to Organon NV, Oss the Netherlands and to
Lilly Nederland B.V, Houten, the Netherlands.
Power calculation
Changes in muscle strength and BMD are the primary
endpoints to judge the efficacy of supplementation with
both study drugs. In order to demonstrate a between-
group difference in handgrip strength of at least 3.6% and
a difference in BMD of at least 2.6%, a power calculation
indicated 75 subjects per group completing the study. To
allow for drop-out and protocol violations, it was calcu-
lated that 324 subjects would need to be recruited, 108 in
each intervention arm. This number is based on conven-
tional assumptions of alpha = 0.05 and beta = 0.2 and a
drop-out of 30%. Mean and SD for handgrip strength
were taken from our previous study on the effect of tibo-
lone in postmenopausal women [13].
Data analysis
Efficacy
Analysis will be done concerning tibolone versus placebo
and raloxifene versus placebo. If both show a significant
beneficial effect, the difference between tibolone and
raloxifene will be analysed. However, this is not expected.
After termination of the Tibolone-arm during our study,
our concern is that the tibolone-placebo comparison will
be underpowered. Analyses will be done with 3 months,
6 months en 12 months (n = 44) data to determine
whether there is a treatment effect of tibolone. In previous
studies with a comparable number of participants or
fewer, a significant beneficial effect was reported on body
composition after 1 year of treatment [43,44], so we
might find an effect as well.
The efficacy analysis will be based on the intention to treat
group (ITT), all subjects of the treated group who had at
least one post baseline assessment of at least one of the
primary outcome variables. In addition a per-protocol
(PP) analysis will be performed, using data for all subjects
from ITT group without any major protocol violation. Dif-
ferences between the ITT and PP results will be examined.
Efficacy parameters
For all parameters, descriptive statistics will be calculated
by treatment group and assessment. In addition, the
change from baseline values will be calculated. If a Gaus-
sian distribution can be assumed, each parameter will be
analyzed by means of a multiple analysis of covariance
model. This model will incorporate treatment group as a
factor and the baseline value as a covariant. Scatter plots
will be used to assess the adequacy of the analysis of cov-
ariance and to detect outliers. Results will be expressed as
estimates of the treatment differences with 95%-confi-
dence intervals and two-sided P-values.
Ethical and regulatory considerations
The study described in this protocol complies with the
current revision of the Declaration of Helsinki, ICH guide-
lines for Good Clinical Practice and local regulatory
requirements.
Conclusion
This trial will analyse the differences in effect of tibolone
and raloxifene on several endpoints. To the best of our
knowledge this randomized controlled double-blind, pla-
cebo-controlled trial is the first to assess the main effect of
tibolone and raloxifene on muscle strength and func-
tional mobility next to bone mineral density in a female
population older than 70 years of age. Research has never
been conducted on the effect of raloxifene on muscle
strength and functional mobility.
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